About
Copy Link
Titles
Hospital Resident
Biography
Undergraduate: Wichita State University, BSN
Interests: Oncology
Last Updated on August 16, 2021.
Education & Training
- MD
- University of Pittsburgh School of Medicine (2021)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Oluwaseun Ayoade's published research.
Publications Timeline
A big-picture view of Oluwaseun Ayoade's research output by year.
Daniel Boffa, MD
Giorgio Caturegli, MD
Maureen Canavan, PhD, MPH
Benjamin Resio, MD
So Yeon Kim, MD
Elizabeth Berger, MD, MS, FACS
13Publications
38Citations
Publications
2026
Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer
Caturegli G, Canavan M, Ayoade O, Boffa D, Resio B. Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer. Clinical Lung Cancer 2026, 27: 48-54.e2. PMID: 42070908, DOI: 10.1016/j.cllc.2026.03.016.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsNon-small cell lung cancerStage III non-small cell lung cancerIII non-small cell lung cancerStage III NSCLC patientsThree-year overall survivalIII NSCLC patientsStage III patientsOutcome of radiationOverall survivalNSCLC patientsIII patientsRadiation patientsNonsurgical optionsLung cancerClinical stage III patientsStage III lung cancerIII lung cancerNational Cancer DatabaseReal-world outcomesCell lung cancerKaplan-Meier curvesStandard treatment approachTotal radiation doseAlternative nonsurgical optionNeoadjuvant chemoimmunotherapyUpdated Review: Using the National Cancer Database for Outcomes-Based Research.
Ayoade O, Caturegli G, Palis B, McCabe R, Weigel R, Canavan M, Boughey J, Boffa D. Updated Review: Using the National Cancer Database for Outcomes-Based Research. Journal Of The American College Of Surgeons 2026 PMID: 41848188, DOI: 10.1097/xcs.0000000000001924.Peer-Reviewed Original ResearchAltmetricConceptsNational Cancer DatabaseFollow-upNon-small cell lung cancerAmerican CollegeCell lung cancerNarrative reviewCancer Reporting SystemCancer-accredited hospitalsPD-L1Tumor gradeTumor sizeCancer DatabaseContinuous tumor sizeLung cancerSmoking statusOutcomes-based researchOncology practiceSurvival dataMedicaid expansion statusOutcome studiesFollow-up limitCancerTreatment reportsPolicy changesPolicy-relevant dataUse of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCohort studyManagement of breast cancerBreast cancerCohort study of dataMedical management of breast cancerTreated with CAMCox proportional hazards modelsMedical managementYear of diagnosisFemale patientsCombination of CAMProportional hazards modelTraditional therapiesAlternative medicineStudy of dataMain OutcomesEndocrine therapyNo treatmentCharlson Comorbidity IndexInsurance typeNonmedical personnelPrimary outcomeFacility typeSurvival timeHazards model
2025
Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer. JTCVS Open 2025, 28: 554-564. PMID: 41473080, PMCID: PMC12745116, DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsErratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]. JTO Clinical And Research Reports 2025, 6: 100850. PMID: 41473839, PMCID: PMC12745935, DOI: 10.1016/j.jtocrr.2025.100850.Commentaries, Editorials and LettersRecent Survival Gains in Stage IV NSCLC by Sociodemographic Strata
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. PMID: 40212792, PMCID: PMC11985032, DOI: 10.1016/j.jtocrr.2025.100798.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-small cell lung cancerStage IV non-small cell lung cancerIV non-small cell lung cancerStage IV NSCLC patientsIV NSCLC patientsCell lung cancerMedian survivalNSCLC patientsLung cancerNon-small cell lung cancer patientsNational Cancer DatabaseKaplan Meier methodTwo-year survivalStratified Cox analysisAdjusted mortality riskMeier methodCancer DatabaseCox analysisEra 1NSCLC treatmentSurvival gainChemotherapy administrationNon-Hispanic blacksPatientsHispanic patients
2024
Barriers to fitness: Disparities in preoperative exercise access for patients with lung cancer
Zolfaghari E, Ayoade O, Antonoff M. Barriers to fitness: Disparities in preoperative exercise access for patients with lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: e39. PMID: 39674938, DOI: 10.1016/j.jtcvs.2024.11.023.Commentaries, Editorials and LettersCitationsAltmetricBrief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Ayoade O, Canavan M, Caturegli G, Boffa D. Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation? Lung Cancer 2024, 198: 108032. PMID: 39561624, DOI: 10.1016/j.lungcan.2024.108032.Peer-Reviewed Original ResearchAltmetricConceptsNon-small cell lung cancerAssociated with superior survivalSuperior survivalStage III NSCLC patientsCancer historyIII NSCLC patientsReceipt of immunotherapyNational Cancer DatabaseRegimens of chemotherapyStage IV patientsAnalyze overall survivalCell lung cancerKaplan Meier analysisStage III andCox proportional hazards modelsProportional hazards modelInnovative treatment approachesInfluence patient outcomesNSCLC patientsIV patientsOverall survivalImmunotherapy trialsCancer DatabaseMeier analysisNon-smallLung Cancer Screening at US Hospitals for People Lacking Primary Care
DeSantis W, Ayoade O, Caturegli G, Boffa D. Lung Cancer Screening at US Hospitals for People Lacking Primary Care. JAMA Network Open 2024, 7: e2442373. PMID: 39480427, PMCID: PMC11528307, DOI: 10.1001/jamanetworkopen.2024.42373.Peer-Reviewed Original ResearchCitationsAltmetricAll compensation isn't equal: Gender disparities continue to exist for industry payments in Cardiothoracic Surgery
Zolfaghari E, Ayoade O, Antonoff M. All compensation isn't equal: Gender disparities continue to exist for industry payments in Cardiothoracic Surgery. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: e17. PMID: 39306794, DOI: 10.1016/j.jtcvs.2024.08.046.Commentaries, Editorials and Letters
News
Copy Link
Get In Touch
Copy Link